Glucagon Secretion – Function, Regulation and Significance
Glucagon secretion refers to the release of the hormone glucagon from the alpha cells of the pancreas. It plays a key role in regulating blood sugar levels and ensuring adequate energy supply throughout the body.
Things worth knowing about "Glucagon Secretion"
Glucagon secretion refers to the release of the hormone glucagon from the alpha cells of the pancreas. It plays a key role in regulating blood sugar levels and ensuring adequate energy supply throughout the body.
What Is Glucagon Secretion?
Glucagon secretion is the process by which the hormone glucagon is released from the alpha cells of the islets of Langerhans in the pancreas into the bloodstream. Glucagon is a critical metabolic hormone that works in opposition to insulin: while insulin lowers blood glucose, glucagon raises it when levels fall too low, making it essential for maintaining glucose homeostasis.
Mechanism of Glucagon Secretion
The release of glucagon is tightly regulated by several stimulating and inhibiting factors:
Stimulation of Secretion
- Low blood glucose (hypoglycemia): The primary trigger for glucagon release is a drop in blood glucose below the normal range.
- Protein-rich meals: Amino acids such as arginine and alanine stimulate glucagon secretion.
- Physical exercise: During endurance exercise or intense physical activity, glucagon secretion increases to maintain energy supply to working muscles.
- Stress hormones: Epinephrine (adrenaline) and activation of the autonomic nervous system also stimulate glucagon release.
Inhibition of Secretion
- High blood glucose (hyperglycemia): Elevated blood glucose, such as after a carbohydrate-rich meal, suppresses glucagon secretion.
- Insulin: Insulin released from neighbouring beta cells directly inhibits glucagon secretion from alpha cells via paracrine signalling.
- Somatostatin: Produced by the delta cells of the pancreas, this hormone suppresses both insulin and glucagon secretion.
- Fatty acids and ketone bodies: Elevated levels of these substrates in the blood can also reduce glucagon release.
Effects of Released Glucagon
Once in the bloodstream, glucagon acts primarily on the liver to:
- Glycogenolysis: Break down glycogen (stored glucose) and release glucose into the blood.
- Gluconeogenesis: Synthesize new glucose from non-carbohydrate sources such as amino acids and glycerol.
- Ketogenesis: During prolonged fasting, glucagon promotes the formation of ketone bodies as an alternative energy source.
These actions ensure that vital organs, especially the brain, receive sufficient energy even during fasting or intense physical activity.
Clinical Significance
Dysregulation of glucagon secretion is associated with several important medical conditions:
- Type 1 Diabetes: In addition to impaired insulin production, glucagon regulation is also disrupted. During hypoglycemia, glucagon secretion is often insufficient, contributing to dangerous low blood sugar episodes.
- Type 2 Diabetes: Glucagon secretion is characteristically elevated even in the presence of high blood glucose, contributing to chronic hyperglycemia.
- Glucagonoma: A rare tumor of the pancreatic alpha cells causing excessive glucagon overproduction, presenting with skin rashes, weight loss, and diabetes-like symptoms.
- Hypoglycemia: An inadequate glucagon response to low blood sugar can lead to severe hypoglycemia, particularly in people with diabetes.
Diagnosis and Measurement
Glucagon secretion can be assessed by measuring plasma glucagon levels. Stimulation tests, such as intravenous arginine infusion, can evaluate the secretory capacity of alpha cells. Clinically, glucagon measurement is used when a glucagonoma is suspected, in the differential diagnosis of hypoglycemia, and in research related to diabetes therapies.
Therapeutic Relevance
Understanding glucagon secretion has direct therapeutic applications:
- Emergency glucagon injection: In cases of severe hypoglycemia, glucagon can be administered by injection or nasal spray to rapidly raise blood glucose levels.
- GLP-1 receptor agonists: Modern antidiabetic medications such as semaglutide and liraglutide work in part by suppressing the excessive glucagon secretion seen in type 2 diabetes.
- Dual agonists: Novel drug classes targeting both GLP-1 and glucagon receptors are under clinical development for the treatment of obesity and diabetes.
References
- Müller, T. D. et al. (2017): Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 6(12), 1394-1406. DOI: 10.1016/j.molmet.2017.09.010
- Unger, R. H. & Cherrington, A. D. (2012): Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. Journal of Clinical Investigation, 122(1), 4-12. DOI: 10.1172/JCI60016
- World Health Organization (WHO): Global Report on Diabetes (2016). WHO Press, Geneva.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Glucagon Secretion-en